136 related articles for article (PubMed ID: 583262)
1. Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves' disease.
McGregor AM; Petersen MM; Capiferri R; Evered DC; Smith BR; Hall R
Clin Endocrinol (Oxf); 1979 Oct; 11(4):437-44. PubMed ID: 583262
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
[TBL] [Abstract][Full Text] [Related]
3. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins.
Atkinson S; McGregor AM; Kendall-Taylor P; Peterson MM; Smith BR
Clin Endocrinol (Oxf); 1982 Jun; 16(6):537-43. PubMed ID: 6125279
[TBL] [Abstract][Full Text] [Related]
4. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy.
Bliddal H; Kirkegaard C; Siersbaek-Nielsen K; Friis T
Acta Endocrinol (Copenh); 1981 Nov; 98(3):364-9. PubMed ID: 6170200
[TBL] [Abstract][Full Text] [Related]
6. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
[TBL] [Abstract][Full Text] [Related]
7. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
Wallaschofski H; Kuwert T; Lohmann T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
[TBL] [Abstract][Full Text] [Related]
8. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
9. Direct and quantitative measurement by immunoprecipitation assay of anti-thyrotrophin receptor antibodies in sera of patients with Graves' disease.
de Bruin TW; van der Heide D; Querido A; Krol MC
Clin Endocrinol (Oxf); 1984 Feb; 20(2):143-51. PubMed ID: 6325045
[TBL] [Abstract][Full Text] [Related]
10. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease.
Kim J; Choi MS; Park J; Park H; Jang HW; Choe JH; Kim JH; Kim JS; Cho YS; Choi JY; Kim TH; Chung JH; Kim SW
Thyroid; 2021 Aug; 31(8):1264-1271. PubMed ID: 33947272
[No Abstract] [Full Text] [Related]
11. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease.
Gamstedt A; Wadman B; Karlsson A
J Clin Endocrinol Metab; 1986 Apr; 62(4):773-7. PubMed ID: 2869050
[TBL] [Abstract][Full Text] [Related]
12. Serum thyrotropin-binding inhibiting immunoglobulin and thyroperoxidase antibody in Graves' hyperthyroidism after 131I therapy.
Hsu CH; Lee LS; Chang JJ; Liao ST; Chen SM; Hwang JY; Lo NI
J Formos Med Assoc; 1995; 94(1-2):5-9. PubMed ID: 7613234
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
[TBL] [Abstract][Full Text] [Related]
14. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
Docter R; Bos G; Visser TJ; Hennemann G
Clin Endocrinol (Oxf); 1980 Feb; 12(2):143-53. PubMed ID: 6105023
[TBL] [Abstract][Full Text] [Related]
15. Vitamin B12 levels are not affected by radioiodine ablation of the thyroid.
Potham SK; Vaikkakara S; Sachan A; Rao SP; Kalawat TC; Ravi P; Sunil E; Rajitha D; Arun M; Sailaja A
Endocr Regul; 2014 Apr; 48(2):77-85. PubMed ID: 24824803
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
17. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis.
Wägar G; Mäkinen T; Lamberg BA; Gordin A; Apter L; Pekonen F
Ann Clin Res; 1982 Apr; 14(2):83-9. PubMed ID: 6184007
[TBL] [Abstract][Full Text] [Related]
18. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
Thyroidology; 1989 Dec; 1(3):109-14. PubMed ID: 2484872
[TBL] [Abstract][Full Text] [Related]
19. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
Chiovato L; Santini F; Vitti P; Bendinelli G; Pinchera A
Clin Endocrinol (Oxf); 1994 Jun; 40(6):803-6. PubMed ID: 8033373
[TBL] [Abstract][Full Text] [Related]
20. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
